Tilray Stock Forecast, Price & News

Tilray's stock was trading at $7.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TLRY stock has increased by 19.9% and is now trading at $8.50.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 3 sell ratings, 10 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Tilray.

Wall Street analysts have given Tilray a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tilray wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Tilray is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Tilray.

Tilray Inc (NASDAQ:TLRY) issued its quarterly earnings results on Monday, November, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.19. The business earned $51.41 million during the quarter, compared to analyst estimates of $54.91 million. Tilray had a negative net margin of 259.60% and a negative return on equity of 77.77%. Tilray's revenue for the quarter was up .6% on a year-over-year basis. During the same period last year, the business earned ($0.36) EPS.
View Tilray's earnings history.

14 brokers have issued 1-year price objectives for Tilray's stock. Their forecasts range from $4.00 to $20.00. On average, they anticipate Tilray's stock price to reach $10.95 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price.
View analysts' price targets for Tilray.

Tilray saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 27,590,000 shares, an increase of 15.8% from the September 30th total of 23,830,000 shares. Based on an average daily trading volume, of 7,210,000 shares, the short-interest ratio is currently 3.8 days.
View Tilray's Short Interest.

Some companies that are related to Tilray include Cronos Group (CRON), Aphria (APHA), Aphria (APHA), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Canopy Rivers (RIV), ChromaDex (CDXC), MediWound (MDWD), Natural Alternatives International (NAII), Charlie's (CHUC), Happiness Biotech Group (HAPP), Sundial Growers (SNDL), Mannatech (MTEX), Glucose Health (GLUC) and FitLife Brands (FTLF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Square (SQ).

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Tilray's stock is owned by a number of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.17%), Princeton Global Asset Management LLC (0.11%), Freestone Capital Holdings LLC (0.09%), LPL Financial LLC (0.04%), Cubist Systematic Strategies LLC (0.03%) and Garde Capital Inc. (0.03%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda, Maryscott Greenwood and Michael Auerbach.
View institutional ownership trends for Tilray.

TLRY stock was sold by a variety of institutional investors in the last quarter, including Princeton Global Asset Management LLC, Freestone Capital Holdings LLC, and FinTrust Capital Advisors LLC. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Christine StClare, Maryscott Greenwood, and Michael Auerbach.
View insider buying and selling activity for Tilray.

TLRY stock was bought by a variety of institutional investors in the last quarter, including Cubist Systematic Strategies LLC, LPL Financial LLC, Garde Capital Inc., California Public Employees Retirement System, National Asset Management Inc., Raymond James & Associates, Cambria Investment Management L.P., and AdvisorShares Investments LLC.
View insider buying and selling activity for Tilray.

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TLRY stock can currently be purchased for approximately $8.50.

Tilray has a market capitalization of $1.13 billion and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Tilray employs 1,646 workers across the globe.

The official website for Tilray is www.tilray.com.

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.